Topiramate as add-on therapy: Pooled analysis of randomized controlled trials in adults

Epilepsia

Volumn 41, Issue SUPPL. 1, 2000, Pages 66-71

  Reife, Ross ^a   Pledger, Gordon ^a   Wu, Shu Chen ^a  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

Adults; Antiepileptic; Partial epilepsy; Topiramate

Indexed keywords

TOPIRAMATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; FEMALE; FOCAL EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FRUCTOSE; HUMANS; MIDDLE AGED; PLACEBOS; RANDOMIZED CONTROLLED TRIALS;

EID: 0034128353     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.2000.tb02175.x     Document Type: Article

References (16)

1. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:1684-90.
2. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Neurology 1996;46:1678-83.
3. Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217-24.
4. Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763-8.
5. Ben-Menachem E, Henriksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-43.
6. Rosenfeld W, Abou-Khalil B, Reife R, Hegadus R, Pledger G, Topiramate YF/YG Study Group. Placebo-controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial-onset epilepsy. Epilepsia 1996;37(suppl 5):153.
7. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
8. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new anti-epileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997;38:859-80.
9. Elferink AJA, Van Zwieten-Boot BJ. Analysis based on number needed to treat shows differences between drugs studied [Letter]. Br Med J 1997;314:603.
10. Walker MC, Sander JWAS. The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology 1996;46:912-4.
11. Edwards KR, Kamin M, Topiramate TPS-TR Study Group. The beneficial effect of slowing the initial titration rate of topiramate. Neurology 1997;48(suppl 2):A39.
12. Sander JWAS. Practical aspects of the use of topiramate in patients with epilepsy. Epilepsia 1997;38(suppl 1):S56-8.
13. Sachedo RC. Topiramate: clinical profile in epilepsy. Clin Pharmacokinet 1998;34:335-46.
14. Gogol LM, Morris HH. The office use of topiramate: a review of seizure control and side-effect profile. Epilepsia 1998;39(suppl 6):55.
15. Singh BK, White-Scott S. Role of topiramate (Topamax®) in adults with intractable epilepsy, mental retardation, and developmental disabilities. Epilepsia 1998;39(suppl 6):55.
16. Gilliam FG. Tolerability of topiramate as monotherapy in patients with recently diagnosed partial epilepsy. Epilepsia 1998;39(suppl 6):56.